MedTrace Logo

Metformin Continuation Versus Interruption Following Coronary Angiography: a Pilot Randomized Controlled Trial

NCT03980990 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2019-06-20

No results posted yet for this study

Summary

This pilot randomized controlled trial aims to evaluate the feasibility for safety examination of continued metformin therapy in patients with type 2 diabetes (T2D) following invasive coronary angiography. Metformin will be continued until coronary angiography.

Conditions

  • Acute Coronary Syndrome
  • Unstable Angina
  • Diabetes Mellitus
  • Metformin Adverse Reaction

Interventions

DRUG

Metformin

Continuation of Metformin

Sponsors & Collaborators

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Jay Shavadia, MD · University of Saskatchewan, Department of Medicine, Division of Cardiology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-17
Primary Completion
2020-06-17
Completion
2020-06-17
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03980990 on ClinicalTrials.gov